Forty-four of the 57 patients included in the ASCO presentation were evaluable for response assessment per protocol. Of the 16 patients with DLBCL enrolled across the dose escalation and expansion phases of the study, 10 were evaluable for disease response at the time of data cut-off. The best responses observed in these patients were CR (2 patients), PR (4 patients) SD (2 patients) and progressive disease, or PD (2 patients), with median duration on treatment of 3 months (range: 1.4-24.2 months, ongoing). The overall median duration on treatment for these 16 patients was 50 days. Objective responses were observed in patients with different subtypes of DLBCL, including germinal center B cell lymphoma (GCB) as well as in 3 patients with t-FL/ DLBCL.
http://files.shareholder.com/downloads/ABEA-5QPVEJ/1856031492x0x866770/1570539B-E9F4-4850-A175-139B5342E0A3/ASH2015CUDC-907.pdf
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM